First results of two multi-center international Phase 1 dose-escalation and -expansion clinical trials of novel T-cell bispecific antibody cibisatamab as…
en_news
Celebrated today at the General Assembly of the Organisation of European Cancer Institutes (OECI), VHIO’s Director and Head of the…
Co-authored by Jaume Capdevila, Medical Oncologist at the Vall d’Hebron University Hospital (HUVH) and Senior Investigator of the Vall d’Hebron…
The ultrasensitive liquid biopsy technique applied in this work is based on the sequencing of the entire tumour genome from…
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with…
Initial data from the IGNYTE clinical trial demonstrate that the combination of the oncolytic virus RP1 and nivolumab (PD-1 immune…
The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment…
The analysis of homologous recombination DNA repair in primary breast and ovarian tumours in patients with pathogenic germline variants in…
In this chapter of Cancer 360 the journalist Adam Martín talks to 8 professionals from VHIO who work in different…
After the success achieved last year, VHIO has once again organized, on April 20, its Open Day, with the aim…
